Getting beyond the immunotherapy divide: a call to action

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
John H. Stewart
Associate director for clinical research, University of Illinois Cancer Center
Robert A. Winn
Director, University of Illinois Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Health and Human Services Secretary Robert F. Kennedy Jr. is moving to overhaul the U.S. Preventive Services Task Force, a highly influential panel that determines which preventive services insurers must cover and guides routine medical care for millions of Americans. 
John H. Stewart
Associate director for clinical research, University of Illinois Cancer Center
Robert A. Winn
Director, University of Illinois Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login